search
Back to results

A Study of CIN-107 in Patients With Uncontrolled Hypertension (HALO)

Primary Purpose

Uncontrolled Hypertension

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
CIN-107
Placebo
Sponsored by
CinCor Pharma, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Uncontrolled Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Is on a stable regimen of background antihypertensive agent(s) for at least 8 weeks and would be considered a candidate for an additional antihypertensive agent at the time of screening ;
  • Has a mean seated systolic blood pressure (SBP) ≥ 140 mmHG;
  • Demonstrates they are able to be adherent to the study drug and their anti-hypertensive medication during a run-in period
  • If taking SGLT2 inhibitor, the regimen must be stable for at least 8 weeks prior to randomization; and
  • Agrees to comply with the contraception and reproduction restrictions of the study;

Exclusion Criteria:

  • Has a mean seated systolic blood pressure (SBP) ≥180 mmHG;
  • Has a body mass index (BMI) >50 kg/m2;
  • Is using alpha or beta blockers for any primary indication other than systemic hypertension (eg, migraine headache);
  • Is not willing or not able to discontinue an MRA or potassium sparing diuretic as part of an existing antihypertensive regimen;
  • Has documented estimated eGFR <30 mL/min/1.73m2;
  • Has known and documented New York Heart Association stage III or IV chronic heart failure;
  • Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before screening;
  • Major cardiac surgery within 6 months before Screening;
  • Has chronic permanent atrial fibrillation;
  • Has uncontrolled diabetes with glycosylated hemoglobin >10% at Screening;
  • Has planned dialysis or kidney transplantation planned during the course of the study;
  • Prior solid organ transplant and/or cell transplants;
  • Sodium <130 mEq/L;
  • Potassium <3.5 mEq/L;
  • Potassium >5 mEq/L;
  • White blood cell count >15 × E9/L or absolute neutrophil count <1 × E9/L at Screening;
  • Is positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen;
  • Has typical consumption of ≥14 alcoholic drinks weekly;

Sites / Locations

  • CinCor Site 27
  • CinCor Site 35
  • CinCor Site 69
  • CinCor Site 6
  • CinCor Site 20
  • CinCor Site 70
  • CinCor Site 36
  • CinCor Site 29
  • CinCor Site 46
  • CinCor Site 47
  • CinCor Site 49
  • CinCor Site 52
  • CinCor Site 57
  • CinCor Site 31
  • CinCor Site 18
  • CinCor Site 41
  • CinCor Site 28
  • CinCor Site 9
  • CinCor Site 1
  • CinCor Site 12
  • CinCor Site 54
  • CinCor Site 13
  • CinCor Site 17
  • CinCor Site 16
  • CinCor Site 34
  • CinCor Site 14
  • CinCor Site 33
  • CinCor Site 40
  • CinCor Site 42
  • CinCor Site 50
  • CinCor Site 72
  • CinCor Site 63
  • CinCor Site 7
  • CinCor Site 21
  • CinCor Site 30
  • CinCor Site 59
  • CinCor Site 19
  • CinCor Site 25
  • CinCor Site 38
  • CinCor Site 38
  • CinCor Site 22
  • CinCor Site 64
  • CinCor Site 11
  • CinCor Site 65
  • CinCor Site 15
  • CinCor Site 24
  • CinCor Site 4
  • CinCor Site 43
  • CinCor Site 60
  • CinCor Site 48
  • CinCor Site 32
  • CinCor Site 68
  • CinCor Site 61
  • CinCor Site 55
  • CinCor Site 3
  • CinCor Site 58
  • CinCor Site 62
  • CinCor Site 26
  • CinCor Site 53
  • CinCor Site 10
  • CinCor Site 45
  • CinCor Site 2
  • CinCor Site 5

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

CIN-107 0.5 mg

CIN-107 1 mg

CIN-107 2 mg

Placebo

Arm Description

Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks

Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks

Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient may remain on CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks or withdraw study participation depending on BP control

Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2mg) and discontinue their background antihypertensive agent(s) for 4 weeks

Outcomes

Primary Outcome Measures

Change From Baseline in Mean Seated Systolic BP (SBP)
The primary efficacy endpoint was the change from baseline in mean seated SBP after 8 weeks of treatment in patients with uncontrolled HTN (Part 1).

Secondary Outcome Measures

Change From Baseline in Mean Seated Diastolic BP (DBP)
The change from baseline in mean seated DBP with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)
Change From Baseline in 24-hour Urine Aldosterone
The change from baseline in 24-hour urine aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1)
Change From Baseline in 24-hour Serum Aldosterone
The change from baseline in 24-hour serum aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1)
Percentage of Patients Achieving a Mean Seated SBP <130 mmHg
The percentage of patients achieving a mean seated SBP <130 mmHg ("responders") with CIN-107 compared to placebo after 8 weeks of treatment (Part 1; Weeks 1 to 8)
Change From Baseline in 24-hour Urine Renin
The change from baseline in 24-hour urine renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)
Change From Baseline in 24-hour Serum Renin
The change from baseline in 24-hour serum renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)

Full Information

First Posted
November 16, 2021
Last Updated
July 28, 2023
Sponsor
CinCor Pharma, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05137002
Brief Title
A Study of CIN-107 in Patients With Uncontrolled Hypertension
Acronym
HALO
Official Title
A Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 8 Weeks of Treatment in Patients With Uncontrolled Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
December 7, 2021 (Actual)
Primary Completion Date
September 13, 2022 (Actual)
Study Completion Date
October 10, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CinCor Pharma, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of multiple dose strengths of baxdrostat (also called CIN-107) in the treatment of patients with uncontrolled hypertension. The primary objective was to demonstrate that treatment with baxdrostat for 8 weeks would lower the systolic blood pressure (SBP) in patients who were hypertensive despite taking one or two anti-hypertensive medications. Participants were assigned to take placebo or baxdrostat once per day for 8 weeks while they continued taking the regular anti-hypertensive medications. At the end of the 8-week period, qualified patients could participate in Part II of the study and receive 2 mg baxdrostat for 4 weeks while they discontinued taking the background anti-hypertensive medication.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uncontrolled Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
249 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CIN-107 0.5 mg
Arm Type
Experimental
Arm Description
Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks
Arm Title
CIN-107 1 mg
Arm Type
Experimental
Arm Description
Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks
Arm Title
CIN-107 2 mg
Arm Type
Experimental
Arm Description
Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient may remain on CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks or withdraw study participation depending on BP control
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2mg) and discontinue their background antihypertensive agent(s) for 4 weeks
Intervention Type
Drug
Intervention Name(s)
CIN-107
Other Intervention Name(s)
Baxdrostat
Intervention Description
CIN-107 tablets by mouth once daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo tablets by mouth once daily
Primary Outcome Measure Information:
Title
Change From Baseline in Mean Seated Systolic BP (SBP)
Description
The primary efficacy endpoint was the change from baseline in mean seated SBP after 8 weeks of treatment in patients with uncontrolled HTN (Part 1).
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in Mean Seated Diastolic BP (DBP)
Description
The change from baseline in mean seated DBP with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)
Time Frame
8 weeks
Title
Change From Baseline in 24-hour Urine Aldosterone
Description
The change from baseline in 24-hour urine aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1)
Time Frame
8 weeks
Title
Change From Baseline in 24-hour Serum Aldosterone
Description
The change from baseline in 24-hour serum aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1)
Time Frame
8 weeks
Title
Percentage of Patients Achieving a Mean Seated SBP <130 mmHg
Description
The percentage of patients achieving a mean seated SBP <130 mmHg ("responders") with CIN-107 compared to placebo after 8 weeks of treatment (Part 1; Weeks 1 to 8)
Time Frame
8 weeks
Title
Change From Baseline in 24-hour Urine Renin
Description
The change from baseline in 24-hour urine renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)
Time Frame
8 weeks
Title
Change From Baseline in 24-hour Serum Renin
Description
The change from baseline in 24-hour serum renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Is on a stable regimen of background antihypertensive agent(s) for at least 8 weeks and would be considered a candidate for an additional antihypertensive agent at the time of screening ; Has a mean seated systolic blood pressure (SBP) ≥ 140 mmHg or ≥ 130 mmHg if diabetic; Demonstrates ability to be adherent to the study drug and their anti-hypertensive medication during a run-in period If taking an SGLT2 inhibitor, the regimen must be stable for at least 8 weeks prior to randomization; and Agrees to comply with the contraception and reproduction restrictions of the study; Exclusion Criteria: Has a mean seated systolic blood pressure (SBP) ≥180 mmHG; Has a body mass index (BMI) >50 kg/m2; Is using alpha or beta blockers for any primary indication other than systemic hypertension (eg, migraine headache); Is not willing or not able to discontinue an MRA or potassium sparing diuretic as part of an existing antihypertensive regimen; Has documented estimated eGFR <30 mL/min/1.73m2; Has known and documented New York Heart Association stage III or IV chronic heart failure; Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before screening; Major cardiac surgery within 6 months before Screening; Has chronic permanent atrial fibrillation; Has uncontrolled diabetes with glycated hemoglobin >10% at Screening; Has planned dialysis or kidney transplantation planned during the course of the study; Prior solid organ transplant and/or cell transplants; Sodium <130 mEq/L; Potassium <3.5 mEq/L; Potassium >5 mEq/L; White blood cell count >15 × E9/L or absolute neutrophil count <1 × E9/L at Screening; Is positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen; Has typical consumption of ≥14 alcoholic drinks weekly;
Facility Information:
Facility Name
CinCor Site 27
City
Saraland
State/Province
Alabama
ZIP/Postal Code
36571
Country
United States
Facility Name
CinCor Site 35
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85712
Country
United States
Facility Name
CinCor Site 69
City
Encinitas
State/Province
California
ZIP/Postal Code
92024
Country
United States
Facility Name
CinCor Site 6
City
Lincoln
State/Province
California
ZIP/Postal Code
95648
Country
United States
Facility Name
CinCor Site 20
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
CinCor Site 70
City
Lynwood
State/Province
California
ZIP/Postal Code
90262
Country
United States
Facility Name
CinCor Site 36
City
Northridge
State/Province
California
ZIP/Postal Code
91324
Country
United States
Facility Name
CinCor Site 29
City
Oceanside
State/Province
California
ZIP/Postal Code
92049
Country
United States
Facility Name
CinCor Site 46
City
Panorama City
State/Province
California
ZIP/Postal Code
91402
Country
United States
Facility Name
CinCor Site 47
City
San Dimas
State/Province
California
ZIP/Postal Code
91773
Country
United States
Facility Name
CinCor Site 49
City
Santa Ana
State/Province
California
ZIP/Postal Code
92705
Country
United States
Facility Name
CinCor Site 52
City
West Hills
State/Province
California
ZIP/Postal Code
91307
Country
United States
Facility Name
CinCor Site 57
City
Denver
State/Province
Colorado
ZIP/Postal Code
80209
Country
United States
Facility Name
CinCor Site 31
City
Waterbury
State/Province
Connecticut
ZIP/Postal Code
06708
Country
United States
Facility Name
CinCor Site 18
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33765
Country
United States
Facility Name
CinCor Site 41
City
Cooper City
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Facility Name
CinCor Site 28
City
Homestead
State/Province
Florida
ZIP/Postal Code
33166
Country
United States
Facility Name
CinCor Site 9
City
Jupiter
State/Province
Florida
ZIP/Postal Code
33458
Country
United States
Facility Name
CinCor Site 1
City
Lake Worth
State/Province
Florida
ZIP/Postal Code
33460
Country
United States
Facility Name
CinCor Site 12
City
Miami
State/Province
Florida
ZIP/Postal Code
33032
Country
United States
Facility Name
CinCor Site 54
City
Miami
State/Province
Florida
ZIP/Postal Code
33106
Country
United States
Facility Name
CinCor Site 13
City
Miami
State/Province
Florida
ZIP/Postal Code
33155
Country
United States
Facility Name
CinCor Site 17
City
Miami
State/Province
Florida
ZIP/Postal Code
33183
Country
United States
Facility Name
CinCor Site 16
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Facility Name
CinCor Site 34
City
Winter Haven
State/Province
Florida
ZIP/Postal Code
33880
Country
United States
Facility Name
CinCor Site 14
City
Buford
State/Province
Georgia
ZIP/Postal Code
30519
Country
United States
Facility Name
CinCor Site 33
City
Addison
State/Province
Illinois
ZIP/Postal Code
60101
Country
United States
Facility Name
CinCor Site 40
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
Facility Name
CinCor Site 42
City
Gurnee
State/Province
Illinois
ZIP/Postal Code
60031
Country
United States
Facility Name
CinCor Site 50
City
Morton
State/Province
Illinois
ZIP/Postal Code
61550
Country
United States
Facility Name
CinCor Site 72
City
Brownsburg
State/Province
Indiana
ZIP/Postal Code
46112
Country
United States
Facility Name
CinCor Site 63
City
West Des Moines
State/Province
Iowa
ZIP/Postal Code
50266
Country
United States
Facility Name
CinCor Site 7
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40503
Country
United States
Facility Name
CinCor Site 21
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40213
Country
United States
Facility Name
CinCor Site 30
City
Marrero
State/Province
Louisiana
ZIP/Postal Code
70072
Country
United States
Facility Name
CinCor Site 59
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70004
Country
United States
Facility Name
CinCor Site 19
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70112
Country
United States
Facility Name
CinCor Site 25
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71106
Country
United States
Facility Name
CinCor Site 38
City
Elkridge
State/Province
Maryland
ZIP/Postal Code
21043
Country
United States
Facility Name
CinCor Site 38
City
Elkridge
State/Province
Maryland
ZIP/Postal Code
21075
Country
United States
Facility Name
CinCor Site 22
City
Troy
State/Province
Michigan
ZIP/Postal Code
48085
Country
United States
Facility Name
CinCor Site 64
City
Olive Branch
State/Province
Mississippi
ZIP/Postal Code
38654
Country
United States
Facility Name
CinCor Site 11
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11201
Country
United States
Facility Name
CinCor Site 65
City
Staten Island
State/Province
New York
ZIP/Postal Code
10305
Country
United States
Facility Name
CinCor Site 15
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45221
Country
United States
Facility Name
CinCor Site 24
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43213
Country
United States
Facility Name
CinCor Site 4
City
Dayton
State/Province
Ohio
ZIP/Postal Code
45377
Country
United States
Facility Name
CinCor Site 43
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73119
Country
United States
Facility Name
CinCor Site 60
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37401
Country
United States
Facility Name
CinCor Site 48
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Facility Name
CinCor Site 32
City
Carrollton
State/Province
Texas
ZIP/Postal Code
75006
Country
United States
Facility Name
CinCor Site 68
City
Dallas
State/Province
Texas
ZIP/Postal Code
75234
Country
United States
Facility Name
CinCor Site 61
City
Georgetown
State/Province
Texas
ZIP/Postal Code
78613
Country
United States
Facility Name
CinCor Site 55
City
Houston
State/Province
Texas
ZIP/Postal Code
77036
Country
United States
Facility Name
CinCor Site 3
City
Houston
State/Province
Texas
ZIP/Postal Code
77040
Country
United States
Facility Name
CinCor Site 58
City
Katy
State/Province
Texas
ZIP/Postal Code
77450
Country
United States
Facility Name
CinCor Site 62
City
Lampasas
State/Province
Texas
ZIP/Postal Code
76550
Country
United States
Facility Name
CinCor Site 26
City
McAllen
State/Province
Texas
ZIP/Postal Code
78501
Country
United States
Facility Name
CinCor Site 53
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78209
Country
United States
Facility Name
CinCor Site 10
City
Sugar Land
State/Province
Texas
ZIP/Postal Code
77479
Country
United States
Facility Name
CinCor Site 45
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84102
Country
United States
Facility Name
CinCor Site 2
City
Manassas
State/Province
Virginia
ZIP/Postal Code
20108
Country
United States
Facility Name
CinCor Site 5
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23510
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study of CIN-107 in Patients With Uncontrolled Hypertension

We'll reach out to this number within 24 hrs